Welcome to our dedicated page for GNCA news (Ticker: GNCA), a resource for investors and traders seeking the latest updates and insights on GNCA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNCA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNCA's position in the market.
Genocea Biosciences (Nasdaq: GNCA) announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial for its GEN-011 therapy. This therapy targets neoantigens using a novel approach involving neoantigen-targeted peripheral T cells (NPTs). The trial aims to assess safety, tolerability, and clinical efficacy. Initial results are expected in late Q4 2021 or Q1 2022. The company emphasizes its ATLAS™ platform for optimizing tumor antigen selection to enhance patient outcomes.
Genocea Biosciences (NASDAQ: GNCA) presented updated data from its GEN-009 Phase 1 trial at the 2021 ASCO Annual Meeting. Four of nine checkpoint inhibitor-sensitive patients showed RECIST responses post-vaccination, with a median duration without disease progression of 15 months. Additionally, six of eight patients in the monotherapy cohort remain disease-free for a median of 25 months. Results show durable T cell responses to neoantigens for at least 6 months. CEO Thomas Davis emphasized the broad immune responses generated by GEN-009 and its potential as a foundation for future therapies.
Genocea Biosciences (NASDAQ: GNCA) provided a business update highlighting its ongoing clinical trials for GEN-011 and GEN-009 targeting neoantigens. The Phase 1/2a trials aim to treat checkpoint inhibitor-refractory patients, with initial efficacy data expected by early 2022. The company reported a cash position of $66 million and a net loss of $12 million for Q1 2021, narrowing from $12.9 million in Q1 2020. Genocea also appointed Jacquelyn Sumer as Chief Legal and Compliance Officer and continues research on SARS-CoV-2 and Inhibigens, which may enhance immunotherapy effectiveness.
Genocea Biosciences (NASDAQ: GNCA) is set to announce its first quarter 2021 financial results and provide a corporate update on April 29, 2021, at 8:30 a.m. ET. Interested parties can join the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) with conference ID 2191366. A live audio webcast will also be available on their investor relations webpage. Genocea is focused on developing immunotherapies for cancer, utilizing its proprietary ATLAS™ platform, and currently advancing two clinical trials for its neoantigen vaccine and adoptive T cell therapy.
Genocea Biosciences (NASDAQ: GNCA) presented preclinical data at the AACR Annual Meeting 2021 regarding Inhibigen-associated effects on cancer immunotherapies. The findings indicate that therapeutic vaccination with an Inhibigen can lead to tumor hyperprogression, effectively reversing protective immune responses intended by standard vaccines. Insights suggest Inhibigens promote an immune-cold tumor environment and suppress T cell responses within four days. Genocea remains committed to excluding Inhibigens from its therapies, focusing on understanding and overcoming immunotherapy resistance.
Genocea Biosciences (NASDAQ: GNCA) announced that CEO Chip Clark will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 2:15 PM ET. A live webcast will be available on the company's investor relations website, with an archived version accessible for 90 days post-conference. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform, which profiles patient T cell responses. Current programs include GEN-009, a neoantigen vaccine, and GEN-011, an adoptive T cell therapy.
Genocea Biosciences, Inc. (NASDAQ: GNCA) announced that CEO Chip Clark will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available as a webcast starting March 9 at 7:00 A.M. ET on the investor section of the Genocea website, where it will remain archived for approximately 90 days. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform to identify effective antigens for treatment.
Genocea Biosciences (NASDAQ: GNCA) reported progress in its clinical trials, particularly with GEN-009 and GEN-011, which focus on neoantigen immunotherapies. The company has initiated the TITAN trial for GEN-011 to evaluate its efficacy in checkpoint inhibitor-refractory patients, expecting results by early 2022. GEN-009 showed promising outcomes with significant tumor volume reduction in some patients. Financially, total cash as of December 31, 2020, was $79.8 million, but the net loss grew to $15 million from $9.4 million in 2019. Genocea's collaborations with leading universities enhance its research capabilities.
Genocea Biosciences (NASDAQ: GNCA) will announce its fourth quarter 2020 financial results and provide a corporate update on February 11, 2021, at 8:30 a.m. ET. Participants can join the call by dialing (844) 826-0619 for domestic or (315) 625-6883 for international access, using conference ID 5767897. Additionally, the event will be available via a live audio webcast on Genocea's investor relations page. A replay will be accessible on the website shortly after the call for 90 days. Genocea focuses on innovative cancer immunotherapies using its ATLAS™ platform.
Genocea Biosciences (NASDAQ: GNCA) announced a significant publication in Cancer Discovery regarding its ATLAS bioassay, which helps develop patient-specific cancer immunotherapies. The research identifies neoantigens driving anti-tumor T cell responses while excluding Inhibigens that promote tumor growth. Key findings indicate that existing T cell responses to neoantigens are more extensive than previously thought, and ATLAS can tailor effective immunotherapies by avoiding harmful Inhibigens. Results from ongoing trials, including GEN-009, show promising immunogenicity and efficacy, paving the way for safer cancer treatments.
